Healthcare

Pharmaxis Ltd (ASX:PXS)

Industry Group : Pharmaceuticals, Biotechnology & Life Sciences | Industry Group Name : Pharmaceuticals

Market Price : AUD 0.105-0.005 (4.546%)

(as on 2022-01-22 10:37:40 AEDT)

Market Cap : AUD 57.637 M

Previous Close Open Close* Day Range 52 WEEK HIGH LOW
0.11 0.11 0.105 0.105L 0.110 H 0.071L 0.150 H
Last Trade 0.105
Change% -4.5455
52 W H/L 0.150/0.071
EBITDA 551,000
NPAT After Abnormal Items -2.97 M
Equity 2.845 M
ROE% -106.15%
Total Liabilities 30.745 M
Total Revenue 23.626 M
Cash and Cash Equivalents 18.712 M

Stock Information

Share price 0.105
Market Cap 57.637 M
Price/Gross Cash Flow 31.95
Dividend Yield Excluding Special 0.00%
Ending Shares 452.824 M
52-Week Range 0.150-0.071
P/E ratio 0.000
Sector P/E --
EPS -0.70
EV/EBITDA 61.89
Net Profit Margin (%) -45.21%
Gross Cash Flows Per Share 0.00
Net Gearing -435.50%
Gross DPS (AUD) 0
Gross Dividend Yield (Annualized) 0.00%
Earnings Yield 0.000
Net Tangible Asset (NTA) 0.00
Sales Per Share 0.02
Book Value Per Share 0.01

Announcements

Heading Date/Time
Investor Presentation  17/11/2021 10:13AM
Proposed issue of securities - PXS  17/11/2021 10:13AM
Placement  17/11/2021 10:10AM
Trading Halt  15/11/2021 8:47AM
FDA Clears PXS Cancer Drug for Phase 2 Liver Cancer Study  09/11/2021 8:47AM
Notification regarding unquoted securities - PXS  05/11/2021 8:50AM
Investor Presentation  04/11/2021 1:28PM
Change of Director's Interest Notice  03/11/2021 1:02PM
Notification regarding unquoted securities - PXS  03/11/2021 1:00PM
Constitution as amended 3 November  03/11/2021 12:20PM
Results of Meeting  03/11/2021 12:14PM
CEO Presentation to 2021 AGM  03/11/2021 8:29AM
Chairman's Address to Shareholders  03/11/2021 8:28AM
Investor Presentation - September Quarterly Update  28/10/2021 12:12PM
Quarterly Activities Report  28/10/2021 8:47AM
Appendix 4C Cash Flow Report  28/10/2021 8:45AM
Pharmaxis Quarterly Shareholder Update and Investor Briefing  25/10/2021 2:10PM
PXS Doses First Patient in Phase 2 Bone Marrow Cancer Trial  13/10/2021 10:59AM
PXS Cleared to Progress to Phase 2 Bone Marrow Cancer Trial  05/10/2021 8:33AM
Corporate Governance Statement  01/10/2021 11:24AM
Appendix 4G  01/10/2021 11:23AM
Notice of Annual General Meeting/Proxy Form  01/10/2021 11:22AM
Annual Report to shareholders  01/10/2021 11:21AM
Change in substantial holding  27/09/2021 8:23AM
Pharmaxis to Present at Biotech Webinar  22/09/2021 2:48PM
Application for quotation of securities - PXS  21/09/2021 4:45PM
Notification of cessation of securities - PXS  20/09/2021 2:38PM
Application for quotation of securities - PXS  20/09/2021 2:11PM
Application for quotation of securities - PXS  09/09/2021 2:14PM

Similar Companies

Related Articles

Load More

About Company

It is a pharmaceutical research company, that is focused on the development of the new therapies for the treatment of diseases pertaining to fibrosis and inflammation such as pulmonary, kidney and liver fibrosis, cancer and inflammatory bowel disease. PXS has its product portfolio under various stages of development.

Corporate Information

company address 20 Rodborough Road, FRENCHS FOREST, NSW, AUSTRALIA, 2086

company phone(02) 9454 7200

company websitehttp://www.pharmaxis.com.au/

Dividends

Year-end Date Franking DPS (AUD) Dividend Yield
30/06/2021 -- 0.000 0.00%
30/06/2020 -- 0.000 0.00%
30/06/2019 -- 0.000 0.00%
30/06/2018 -- 0.000 0.00%
30/06/2017 -- 0.000 0.00%
30/06/2016 -- 0.000 0.00%
30/06/2015 -- 0.000 0.00%
30/06/2014 -- 0.000 0.00%
30/06/2013 -- 0.000 0.00%
30/06/2012 -- 0.000 0.00%

Event Calendar

Event Type Event Date Event Year
Report (Annual) 2022-09-30 2022
Report (Prelim) 2022-08-11 2022
Report (Interim) 2022-02-09 2022

Financials

Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Trading Revenue 6.68 M 7.027 M 5.676 M 6.094 M 4.823 M
Other Revenue 16.946 M 5.638 M 6.495 M 44.141 M 12.475 M
Total Revenue 23.626 M 12.665 M 12.171 M 50.235 M 17.298 M
Interest Income 50,000 2.524 M 909,000 598,000 703,000
Interest Expenses -369,000 0 -238,000 -563,000 -623,000
Expenses -23.175 M -25.896 M -30.281 M -73.05 M -32.665 M
EBITDA 451,000 -13.231 M -18.11 M -22.815 M -15.367 M
Depreciation and Amortization -3.152 M -3.236 M -2.619 M -3.35 M -3.059 M
Depreciation -3.01 M -3.107 M -2.523 M -3.247 M -3.006 M
Amortisation -142,000 -129,000 -96,000 -103,000 -53,000
EBIT -2.701 M -16.467 M -20.729 M -26.165 M -18.426 M
Pre Tax Profit -3.02 M -13.943 M -20.058 M -26.13 M -18.346 M
Tax Expense 0 0 0 8,000 0
Net Profit After Tax -3.02 M -13.943 M -20.058 M -26.122 M -18.346 M
Minority Interest 0 0 0 0 0
Preference Dividend 0 0 0 0 0
Net Abnormal Items 50,000 0 0 32.55 M 0
Reported Net Profit After Abnormal Items -2.97 M -13.943 M -20.058 M 6.428 M -18.346 M
Ending Shares 452.824 M 395.249 M 394.316 M 319.778 M 319.107 M
Weighted Average Shares 407.283 M 394.743 M 381.393 M 319.672 M 318.516 M
EPS After Abnormal Items (cents) -0.73 -3.53 -5.26 2.01 -5.76
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Total Current Assets 25.309 M 24.492 M 40.575 M 35.984 M 28.643 M
Total Non Current Assets 8.281 M 10.924 M 12.093 M 14.113 M 16.791 M
Total Assets 33.59 M 35.416 M 52.668 M 50.097 M 45.434 M
Total Current Liabilities 7.887 M 6.825 M 8.112 M 8.244 M 10.521 M
Total Non Current Liabilities 22.858 M 27.16 M 29.742 M 30.735 M 31.392 M
Total Liabilities 30.745 M 33.985 M 37.854 M 38.979 M 41.913 M
Net Assets 2.845 M 1.431 M 14.814 M 11.118 M 3.521 M
Breakdown 30/06/2021 30/06/2020 30/06/2019 30/06/2018 30/06/2017
Net Operating Cash 3.072 M -13.284 M -19.798 M 12.206 M -15.262 M
Net Invested Cash -644,000 -574,000 -981,000 -884,000 -723,000
Net Financing Cash Flows 1.52 M -2.502 M 20.83 M -1.753 M -1.721 M
Beginning Cash 14.764 M 31.124 M 31.073 M 21.504 M 39.209 M
End Cash Position 18.712 M 14.764 M 31.124 M 31.073 M 21.504 M
Exchange Rate Adjustments 0 0 0 0 1,000
Other Cash Adjustments 0 0 0 0 0
Ending Cash 18.712 M 14.764 M 31.124 M 31.073 M 21.504 M

© Morningstar, Inc. 2021. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the market indices, commodities and regulatory news headlines, and other data or content contained herein to be accurate, complete, or timely, and nor shall they have any liability for its use or distribution. The data contained herein: (1) is proprietary to Morningstar and/or its affiliates (collectively, “Morningstar”) and/or their content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete, or timely. Our publications, ratings and products should be viewed as an additional investment resource, and not as your sole source of information. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your financial situation, contact a professional financial adviser. Some material is copyrighted and published under licence from ASX Operations Pty. Ltd. ACN 004523782.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK